Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.45 – $0.74
10% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $6.7M | $9.3M | $11.0M | $14.0M | $35.8M | $58.5M | $103.8M |
| Cost of revenue | $8.4M | $15.3M | $17.2M | $15.9M | $18.4M | $27.4M | $38.4M | $72.7M |
| Gross profit | −$5.2M | −$8.5M | −$7.9M | −$4.9M | −$4.4M | $8.3M | $20.1M | $31.1M |
| Gross margin | -162.6% | -127.2% | -84.6% | -44.8% | -31.3% | 23.3% | 34.4% | 30.0% |
| R&D | $801.0K | $4.8M | $8.2M | $12.5M | $19.5M | $19.4M | $22.2M | $22.8M |
| Operating income | −$26.8M | −$36.4M | −$48.9M | −$84.2M | −$133.9M | −$137.4M | −$124.1M | −$120.7M |
| EBITDA | −$21.3M | −$23.4M | −$37.0M | −$73.2M | −$120.1M | −$115.9M | −$95.5M | −$96.3M |
| Net income | −$25.6M | −$33.7M | −$47.4M | −$82.1M | −$132.7M | −$134.1M | −$118.7M | −$137.1M |
| Net margin | -797.2% | -501.8% | -508.1% | -748.1% | -945.6% | -375.2% | -203.0% | -132.1% |
| EPS (diluted) | -0.57 | -0.66 | -0.83 | -1.30 | -1.96 | -1.45 | -0.95 | -0.93 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $152M | $-0.20 | $-0.20–$-0.20 | 1 |
| 2027 | $232M | $0.54 | $0.54–$0.54 | 1 |
| 2028 | $330M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
SENZIME AB ORD
No one on the platform currently holds SNZZF.
No tracked institution reports a position in SNZZF as of their last filing.
No one on the platform has traded SNZZF yet.
| $74M |
| — |
| PBIGFParadigm Biopharmaceuticals Limited | $0.13 | -10.20% | $57M | — |
| PFGTFPacific Edge Limited | $0.17 | +0.00% | $212M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.8× sales vs its 1.4× historical median P/S.
Fair value ≈ $0.83 · price $0.48 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.